Sustained effects of resveratrol on circulatory function in obese adults

A 12-week, randomised, double-blind, placebo controlled study of the sustained effects of ResvidaTM on circulatory function and cognition in obese adults

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12611000060943

Enrollment

Registered

2011-01-17

Start date

2011-03-07

Completion date

2011-06-15

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

It is well established that obesity can lead to impaired vascular function. This not only leads to cardiovascular health consequences but may also impact on cognitive function by impairing the delivery of blood flow to the brain. We have recently demonstrated an acute, dose dependent improvement of flow mediated dilatation (FMD) with resveratrol supplementation (ACTRN12609000023257). However, the effects of chronic supplementation are still unknown. FMD is a non-invasive means of assessing blood vessel function. We will now determine whether regular daily consumption of resveratrol for 6 weeks can lead to a sustained improvement in FMD which may result in a decrease in resting BP and enhance cognitive performance. This could be particularly advantageous in potentially improving long term cardiovascular and mental health. The investigation will be undertaken in obese subjects as they are more likely to have impaired FMD without other established risk factors for cardiovascular disease.

Interventions

Volunteers will consume a 75 mg dose of resveratrol (resVida 'Trademark (TM)', DSM Nutritional Products, Switzerland) daily for 6 weeks. This supplement will be delivered orally in capsule form. There will be three separate visits to the Nutritional Physiology Research Centre (of 2 hours duration each), baseline, week 6 then crossed over to alternate dose (active or placebo), then assessments at week 12. There is no washout between the active and placebo arm.

Study design

Allocation

Randomised controlled trial

Intervention model

Crossover

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

40 Years to 75 Years

Healthy volunteers

Inclusion criteria

Men or post-menopausal women (self reported cessation of menses for at least 12 months) Age: 40-70 years. Obese (BMI 30-45 kg/m2) but otherwise healthy

Exclusion criteria

- Supine BP above SBP 160 mmHg or DBP 100 mmHg - Having cardiovascular disease, renal disease or diabetes - Taking BP lowering medication - Having any other medical condition or treatments (including supplements) which, in the opinion of the investigators, may influence the outcome of the study - Smokers or those using nicotine replacement therapy - Those unwilling to restrict food items containing high amounts of polyphenols (grape, grape juice, wine, peanuts, peanut butter, mulberries, green tea, soy and soy products)

Outcome results